Golden State Equity Partners Apellis Pharmaceuticals, Inc. Transaction History
Golden State Equity Partners
- $182 Million
- Q3 2024
A detailed history of Golden State Equity Partners transactions in Apellis Pharmaceuticals, Inc. stock. As of the latest transaction made, Golden State Equity Partners holds 1,050 shares of APLS stock, worth $31,636. This represents 0.02% of its overall portfolio holdings.
Number of Shares
1,050Holding current value
$31,636% of portfolio
0.02%Shares
1 transactions
Others Institutions Holding APLS
# of Institutions
310Shares Held
113MCall Options Held
3.85MPut Options Held
1.09M-
Wellington Management Group LLP Boston, MA15.6MShares$469 Million0.08% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA11.9MShares$358 Million14.88% of portfolio
-
Avoro Capital Advisors LLC New York, NY11.1MShares$335 Million4.82% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.82MShares$296 Million0.01% of portfolio
-
Black Rock Inc. New York, NY5.8MShares$175 Million0.01% of portfolio
About Apellis Pharmaceuticals, Inc.
- Ticker APLS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 109,865,000
- Market Cap $3.31B
- Description
- Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...